Cigarette smoke modulates PC3 prostate cancer cell migration by altering adhesion molecules and the extracellular matrix

Molecular Medicine Reports

Volumn 12, Issue 5, 2015, Pages 6990-6996

  Yang, Suping ^a   Long, Minica ^a   Tachado, Souvenir D ^a   Seng, Seyha ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cell adhesion molecules; Cell migration; Cigarette smoke; Extracellular matrix; Prostate cancer

Indexed keywords

CD18 ANTIGEN; CELL ADHESION MOLECULE; CIGARETTE SMOKE; COLLAGENASE 3; GELATINASE A; MATRILYSIN; SMALL INTERFERING RNA; THROMBOSPONDIN 2;

ARTICLE; CELL CULTURE; CELL MIGRATION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; KALLMANN SYNDROME; MALE; PARTICULATE MATTER; POLYMERASE CHAIN REACTION; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; RNA ISOLATION; RNA TRANSCRIPTION; SMOKING; TUMOR GROWTH; WOUND HEALING; ADENOCARCINOMA; ADVERSE EFFECTS; CELL MOTION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PROSTATE; PROSTATE TUMOR; TUMOR CELL LINE;

ADENOCARCINOMA; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CELL MOVEMENT; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PROSTATE; PROSTATIC NEOPLASMS; SMOKING;

EID: 84943592942     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.4302     Document Type: Article

References (49)

1. Siegel R, Ward E, Brawley O and Jemal A: Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-236, 2011.
2. Chan JM, Jou RM and Carroll PR: The relative impact and future burden of prostate cancer in the United States. J Urol 172: S13-S16, 2004.
3. Huncharek M, Haddock KS, Reid R and Kupelnick B: Smoking as a risk factor for prostate cancer: A meta-analysis of 24 prospective cohort studies. Am J Public Health 100: 693-701, 2010.
4. Stewart S L, Cardinez CJ, Richardson LC, et al: Surveillance for cancers associated with tobacco use . United States, 1999-2004. MMWR Surveill Summ 57: 1-33, 2008.
5. Colditz G: Consensus conference: smoking and prostate cancer. Cancer Causes Control 7: 560-562, 1996.
6. Hickey K, Do KA and Green A: Smoking and prostate cancer. Epidemiol Rev 23: 115-125, 2001.
7. Rohrmann S, Linseisen J, Allen N, et al: Smoking and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition. Br J Cancer 108: 708-714, 2013.
8. Zu K and Giovannucci E: Smoking and aggressive prostate cancer: A review of the epidemiologic evidence. Cancer Causes Control 20: 1799-1810, 2009.
9. Roomi MW, Kalinovsky T, Rath M, et al: Down-regulation of urokinase plasminogen activator and matrix metalloproteinases and up-regulation of their inhibitors by a novel nutrient mixture in human prostate cancer cell lines PC-3 and DU-145. Oncol Rep 26: 1407-1413, 2011.
10. Yurchenco PD and Schittny JC: Molecular architecture of basement membranes. FASEB J 4: 1577-1590, 1990.
11. Barsky SH, Siegal GP, Jannotta F, et al: Loss of basement membrane components by invasive tumors but not by their benign counterparts. Lab Invest 49: 140-147, 1983.
12. Liotta LA, Tryggvason K, Garbisa S, et al: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284: 67-68, 1980.
13. Liotta LA, Rao CN and Barsky SH: Tumor invasion and the extracellular matrix. Lab Invest 49: 636-649, 1983.
14. Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-174, 2002.
15. Folkman J: Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29: 15-18, 2002.
16. Chambers AF and Matrisian LM: Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89: 1260-1270, 1997.
17. Nelson AR, Fingleton B, Rothenberg ML, et al: Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18: 1135-1149, 2000.
18. Berube M, Deschambeault A, Boucher M, et al: MMP-2 expression in uveal melanoma: differential activation status dictated by the cellular environment. Mol Vis 11: 1101-1111, 2005.
19. Garzetti G, Ciavattini A, Lucarini G, et al: Tissue and serum metalloproteinase (MMP-2) expression in advanced ovarian serous cystoadenocarcinomas: clinical and prognostic implications. Anticancer Res 15: 2799-2804, 1995.
20. Gohji K, Fujimoto N, Hara I, Fujii A, Gotoh A, et al: Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension. Int J Cancer 79: 96-101, 1998.
21. Lokeshwar BL: MMP inhibition in prostate cancer. Ann NY Acad Sci 878: 271-289, 1999.
22. Shariat SF, Karam JA and Roehrborn CG: Blood biomarkers for prostate cancer detection and prognosis. Future Oncol 3: 449-461, 2007.
23. Achbarou A, Kaiser S, Tremblay G, et al: Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res 54: 2372-2377, 1994.
24. Pryor WA and Stone K: Oxidants in cigarette smoke. Radicals, hydrogen peroxide, peroxynitrate, and peroxynitrite. Ann NY Acad Sci 686: 12-27, 1993.
25. Hecht SS: Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 91: 1194-1210, 1999.
26. Birrane G, Li H, Yang S, et al: Cigarette smoke induces nuclear translocation of heme oxygenase 1 (HO-1) in prostate cancer cells: nuclear HO-1 promotes vascular endothelial growth factor secretion. Int J Oncol 42: 1919-1928, 2013.
27. Aragon-Ching JB: Active surveillance for prostate cancer: has the time finally come? J Clin Oncol 28: e265-e266, 2010.
28. Dilly AK, Ekambaram P, Guo Y, et al: Platelet-type 12-lipoxygenase induces MMP9 expression and cellular invasion via activation of PI3K/Akt/NF-κB. Int J Cancer 133: 1784-1791, 2013.
29. Tian TV, Tomavo N, Huot L, et al: Identification of novel TMPRSS2:ERG mechanisms in prostate cancer metastasis: involvement of MMP9 and PLXNA2. Oncogene 24: 2204-2214 2014.
30. Delassus GS, Cho H, Hoang S and Eliceiri GL: Many new down. and up-regulatory signaling pathways, from known cancer progression suppressors to matrix metalloproteinases, differ widely in cells of various cancers. J Cell Physiol 224: 549-558, 2010.
31. Verslegers M, Lemmens K, Van Hove I and Moons L: Matrix metalloproteinase-2 and .9 as promising benefactors in development, plasticity and repair of the nervous system. Prog Neurobiol 105: 60-78, 2013.
32. Jinka R, Kapoor R, Sistla PG, Raj TA and Pande G: Alterations in cell-extracellular matrix interactions during progression of cancers. Int J Cell Biol 2012: 219196, 2012.
33. Yoo SY and Kwon SM: Angiogenesis and its therapeutic opportunities. Mediators Inflamm 2013: 127170, 2013.
34. Grassel S and Bauer RJ: Collagen XVI in health and disease. Matrix Biol 32: 64-73, 2013.
35. Goel HL, Li J, Kogan S and Languino LR: Integrins in prostate cancer progression. Endocr Relat Cancer 15: 657-664, 2008.
36. Vandewalle C, Van Roy F and Berx G: The role of the ZEB family of transcription factors in development and disease. Cell Mol Life Sci 66: 773-787, 2009.
37. Xiao LJ, Lin P, Lin F, et al: ADAM17 targets MMP-2 and MMP-9 via EGFR-MEK-ERK pathway activation to promote prostate cancer cell invasion. Int J Oncol 40: 1714-1724, 2012.
38. Ashida S, Nakagawa H, Katagiri T, et al: Molecular features of the transition from prostatic intraepithelial neoplasia (PIN) to prostate cancer: genome-wide gene-expression profiles of prostate cancers and PINs. Cancer Res 64: 5963-5972, 2004.
39. Sathyanarayana UG, Padar A, Suzuki M, et al: Aberrant promoter methylation of laminin-5-encoding genes in prostate cancers and its relationship to clinicopathological features. Clin Cancer Res 9: 6395-6400, 2003.
40. Rodriguez LG, Wu X and Guan JL: Wound-healing assay. Methods Mol Biol 294: 23-29, 2005.
41. Gumbiner BM: Cell adhesion: The molecular basis of tissue architecture and morphogenesis. Cell 84: 345-357, 1996.
42. Sheetz MP, Felsenfeld DP and Galbraith CG: Cell migration: regulation of force on extracellular-matrix-integrin complexes. Trends Cell Biol 8: 51-54, 1998.
43. Zhen Y, Ye Y, Yu X, et al: Reduced CTGF expression promotes cell growth, migration, and invasion in nasopharyngeal carcinoma. PLoS One 8: e64976, 2013.
44. Jinka R, Kapoor R, Sistla PG, Raj TA and Pande G: Alterations in cell-extracellular matrix interactions during progression of cancers. Int J Cell Biol 2012: 219196, 2012.
45. Okegawa T, Pong RC, Li Y and Hsieh JT: The role of cell adhesion molecule in cancer progression and its application in cancer therapy. Acta Biochim Pol 51: 445-457, 2004.
46. Zhao Y, Zhou T, Li A, et al: A potential role of collagens expression in distinguishing between premalignant and malignant lesions in stomach. Anat Rec (Hoboken) 292: 692-700, 2009.
47. Fischer H, Salahshor S, Stenling R, et al: COL11A1 in FAP polyps and in sporadic colorectal tumors. BMC Cancer 1: 17, 2001.
48. Wu YH, Chang TH, Huang YF, et al: COL11A1 promotes tumor progression and predicts poor clinical outcome in ovarian cancer. Oncogene 33: 3432-3440, 2014.
49. Nabha SM, dos Santos EB, Yamamoto HA, et al: Bone marrow stromal cells enhance prostate cancer cell invasion through type I collagen in an MMP-12 dependent manner. Int J Cancer 122: 2482-2490, 2008.